Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation.

Journal:

The Journal of antimicrobial chemotherapy, Volume: 73, Issue: 7

Published:

July 1, 2018

PMID:

29584861

Authors:

James Millard J, Henry Pertinez H, Laura Bonnett L, Eva Maria Hodel EM, Véronique Dartois V, John L Johnson JL, Maxine Caws M, Simon Tiberi S, Mathieu Bolhuis M, Jan-Willem C Alffenaar JC, Geraint Davies G, Derek J Sloan DJ

Access Paper

DOI: 10.1093/jac/dky096

PMID: 29584861

Abstract:

The oxazolidinone linezolid is an effective component of drug-resistant TB treatment, but its use is limited by toxicity and the optimum dose is uncertain. Current strategies are not informed by clinical pharmacokinetic (PK)/pharmacodynamic (PD) data; we aimed to address this gap.

Courtesy of the U.S. National Library of Medicine